The prevalence of type 2 diabetes, along with related conditions, such as metabolic syndrome and obesity, has increased ...

Shares of Regeneron Pharmaceuticals Inc. REGN slumped 0.17% to $1,012.82 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.90% ...

This week, the FDA granted approval to Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for its sixth indication.

Biotech company Regeneron Pharmaceuticals lost a bid on Friday to be held immune from allegations that it misused a patented ...

Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $1014.59 which represents a decrease of $-25.68 or -2.47% from the prior close of $1040.27. The stock opened at $1037.5 and ...

Currently trading with a volume of 421,493, the REGN's price is down by 0.0%, now at $1040.27. RSI readings suggest the stock ...

Regeneron Pharmaceuticals, a biotechnology firm based in Tarrytown, New York, has purchased the former Quad Graphics printing facility in Saratoga Springs for an undisclosed sum. “This acquisition ...

A new trial highlights that the timing of chemoradiation and immunotherapy is crucial when treating limited-stage small cell ...

Discover the top biotech companies pioneering the next healthcare breakthroughs. Learn how innovative firms are ...

The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.

To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through ...

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...